Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors

Cholecystokinin (CCK) receptors are overexpressed in numerous human cancers, like medullary thyroid carcinomas, small cell lung cancers and stromal ovarian cancers. The specific receptor-binding property of the endogenous ligands for these receptors can be exploited by labeling peptides with a radionuclide and using these as carriers to guide the radioactivity to the tissues that express the receptors. In this way, tumors can be visualized using positron emission tomography and single photon emission computed tomography imaging. A variety of radiolabeled CCK/gastrin-related peptides has been synthesized and characterized for imaging. All peptides have the C-terminal CCK receptor-binding tetrapeptide sequence Trp-Met-Asp-Phe-NH2 in common or derivatives thereof. This review focuses on the development and application of radiolabeled CCK/gastrin peptides for radionuclide imaging and radionuclide therapy of tumors expressing CCK receptors. We discuss both preclinical studies as well as clinical studies with CCK and gastrin peptides.

[1]  E. Krenning,et al.  Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma , 2000, European Journal of Nuclear Medicine.

[2]  R. Valkema,et al.  Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  J. Erion,et al.  Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo , 1998, European Journal of Nuclear Medicine.

[4]  W. Oyen,et al.  Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  W. Oyen,et al.  Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. , 2010, Bioconjugate chemistry.

[6]  W. Oyen,et al.  Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. , 2008, European journal of nuclear medicine and molecular imaging.

[7]  H. Hellmich,et al.  Human Colorectal Cancers Express a Constitutively Active Cholecystokinin-B/Gastrin Receptor That Stimulates Cell Growth* , 2000, The Journal of Biological Chemistry.

[8]  W. Oyen,et al.  Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists. , 2006, Nuclear medicine and biology.

[9]  S. Snyder,et al.  Distinct cholecystokinin receptors in brain and pancreas. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Iwata,et al.  Cholecystokinin-B/gastrin receptor: a novel molecular probe for human small cell lung cancer. , 1995, Cancer research.

[11]  L. F. Kolakowski,et al.  Expression cloning and characterization of the canine parietal cell gastrin receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Vanderhaeghen,et al.  New peptide in the vertebrate CNS reacting with antigastrin antibodies , 1975, Nature.

[13]  J C Reubi,et al.  Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. , 1997, Cancer research.

[14]  I. Zagon,et al.  Characterization of the CCK-C (cancer) receptor in human pancreatic cancer. , 2002, International journal of molecular medicine.

[15]  T. Wheldon,et al.  Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  M. Béhé,et al.  Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. , 2002, Seminars in nuclear medicine.

[17]  B. Roques,et al.  CCK-B receptor: chemistry, molecular biology, biochemistry and pharmacology , 1999, Progress in Neurobiology.

[18]  E. Krenning,et al.  Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  M. Béhé,et al.  CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M. Ocak,et al.  Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation. , 2009, Journal of medicinal chemistry.

[21]  J C Reubi,et al.  Unexpected high incidence of cholecystokinin‐B/gastrin receptors in human medullary thyroid carcinomas , 1996, International journal of cancer.

[22]  U. Haberkorn,et al.  (68)Ga-labeled peptides in tumor imaging. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  W. Oyen,et al.  Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Roland Haubner,et al.  αvβ3-integrin imaging: a new approach to characterise angiogenesis? , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  J. Fichna,et al.  Synthesis of target-specific radiolabeled peptides for diagnostic imaging. , 2003, Bioconjugate chemistry.

[26]  Michele Saviano,et al.  Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystokinin Type B Receptor , 2006, ChemMedChem.

[27]  Pomila Singh,et al.  Clinical significance of gastrin receptors in human colon cancers. , 1989, Cancer research.

[28]  W. Oyen,et al.  Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. , 2004, Bioconjugate chemistry.

[29]  A. Ivy,et al.  A HORMONE MECHANISM FOR GALL-BLADDER CONTRACTION AND EVACUATION , 1928 .

[30]  M. Walter,et al.  Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  J. Hughes,et al.  Cholecystokinin receptors , 2005, Cellular and Molecular Neurobiology.

[32]  L. Miller,et al.  CCK2 receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours , 2009, Journal of cellular and molecular medicine.

[33]  M. Salvatore,et al.  In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  M. Béhé,et al.  Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin , 1998, European Journal of Nuclear Medicine.

[35]  J Nucl Med , 2010 .

[36]  J. Williams,et al.  Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. , 1980, The Journal of biological chemistry.

[37]  S. Wank,et al.  G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. , 1998, The American journal of physiology.

[38]  M. Salvatore,et al.  In vitro and in vivo characterization of Indium-111 and Technetium-99m labeled CCK-8 derivatives for CCK-B receptor imaging. , 2004, Cancer biotherapy & radiopharmaceuticals.

[39]  M. Béhé,et al.  Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  M. Béhé,et al.  Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. , 2002, Biopolymers.

[41]  M. Béhé,et al.  Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  S. Wank.  I. CCK receptors: an exemplary family. , 1998, American journal of physiology. Gastrointestinal and liver physiology.

[43]  O. Boerman,et al.  Synthesis and biological evaluation of potent a v h 3 -integrin receptor antagonists , 2006 .

[44]  S. Watson,et al.  Selection of Radiolabeled Gastrin Analogs for Peptide Receptor–Targeted Radionuclide Therapy , 2007, Journal of Nuclear Medicine.

[45]  G. Baldwin,et al.  Expression of gastrin, gastrin/CCK-B and gastrin/CCK-C receptors in human colorectal carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[46]  E. Krenning,et al.  Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides. , 2008, Nuclear medicine and biology.

[47]  R. Haubner.  Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? , 2006, European journal of nuclear medicine and molecular imaging.

[48]  J. Crawley,et al.  International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.

[49]  B. Maigret,et al.  Insights into the binding and activation sites of the receptors for cholecystokinin and gastrin , 2008, Regulatory Peptides.

[50]  M. Béhé,et al.  Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives , 2003, European Journal of Nuclear Medicine and Molecular Imaging.